Figure Technology Solutions, Inc. (FIGR) Q3 2025 Earnings Call Transcript — Neutral
FIGR Seeking Alpha — November 18, 2025Figure Technology Solutions, Inc. ( FIGR ) Q3 2025 Earnings Call November 14, 2025 8:30 AM EST Company Participants Michael Tannenbaum - CEO & Director Michael Cagney - Co-Founder & Executive Chairman Minchung Kgil - Chief Financial Officer Conference Call Participants Dan Dolev - Mizuho Securities USA LLC, Research Division James Yaro - Goldman Sachs Group, Inc., Research Division Patrick Moley - Piper Sandler & Co., Research Division Ryan Tomasello - Keefe, Bruyette, & Woods, Inc., Research Division Robert Wildhack - Autonomous Research US LP Daniel Fannon - Jefferies LLC, Research Division Craig Siegenthaler - BofA Securities, Research Division Presentation …
Paramount preps $71 billion Warner Bros Discovery bid with Arab sovereign wealth funds, Variety reports — Positive
PSKY WBD Reuters — November 18, 2025Paramount Skydance has formed an investment consortium with the sovereign wealth funds of Saudi Arabia, Qatar and Abu Dhabi to submit a total $71 billion bid for Warner Bros Discovery , Variety reported on Tuesday, citing sources familiar with the matter.
New RSA Agent for Admin Threats Now Generally Available in Microsoft Security Copilot — Neutral
MSFT Business Wire — November 18, 2025SAN FRANCISCO--(BUSINESS WIRE)--RSA Security today announced the general availability of its RSA Advisor for Admin Threats agent in Microsoft Security Copilot. “AI is the force multiplier for defenders, and when partners bring their agentic innovation into the Security Copilot ecosystem, the impact is exponential. Together, we're not just building tools—we're creating a new era of intelligent, collaborative cyber defense.” - Vasu Jakkal, Corporate Vice President, Microsoft Security. “We acceler.
Mission Produce's U.K. Hub Gains Traction: Is Europe the Next Big Bet? — Positive
AVO Zacks Investment Research — November 18, 2025AVO's U.K. momentum fuels its Europe push, with rising demand and stronger retailer ties pointing to the company's next major growth frontier.
People were booking their Thanksgiving flights at a fast clip. Here's why that ended. — Negative
AAL DAL JBLU LUV UAL Market Watch — November 18, 2025U.S. airlines will see an impact of those slower bookings in their fourth quarter, which usually ties with second quarter and the start of the summer as their strongest for sales.
ATTENTION NYSE: JHX INVESTORS: Contact Berger Montague About a James Hardie Industries PLC Class Action Lawsuit — Neutral
JHX PRNewsWire — November 18, 2025PHILADELPHIA , Nov. 18, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against James Hardie Industries plc (NYSE: JHX) ("James Hardie" or the "Company") on behalf of investors who purchased James Hardie common stock or American Depositary Shares during the period of May 20, 2025 through August 18, 2025 (the "Class Period"). Investor Deadline: Investors who purchased James Hardie securities during the Class Period may, no later than December 23, 2025 , seek to be appointed as a lead plaintiff representative of the class.
FingerMotion Announces Strategic Roadmap to Drive Regional Expansion and Shareholder Value — Neutral
FNGR Newsfile Corp — November 18, 2025Singapore, Singapore--(Newsfile Corp. - November 18, 2025) - FingerMotion, Inc. (NASDAQ: FNGR) ("FingerMotion" or the "Company"), a mobile services, data, and technology company, today announces the next phase of its strategic roadmap, which focuses on expanding its technology platforms and monetizing the core competencies developed in China for broader regional markets. Over the past years, FingerMotion has built a strong foundation through its mobile recharge and top-up platform, data-driven analytics, and technology collaborations across multiple sectors.
Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights — Neutral
SKYE Business Wire — November 18, 2025NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Skye Bioscience, Inc. (NASDAQ: SKYE) securities between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”). Skye is a clinical stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Alleg.
WW International: First Normal Quarter Shows Signs Of Stability — Positive
WW Seeking Alpha — November 18, 2025WW International (WW) delivered a strong Q3, exceeding revenue and EBITDA expectations, driven by its Clinical Business. WW faces ongoing challenges, including declining Behavioral subscribers and cautious Q4 guidance, which may keep investors wary until trends improve. Key catalysts ahead include FDA decisions on GLP-1 compounding, expanded insurance coverage, and new partnerships with pharma and insurance providers.
This TQQQ Chart Made Me Rethink Long-Term Leveraged Investing — Positive
TQQQ Seeking Alpha — November 18, 2025TQQQ is the cleanest, most liquid 3x Nasdaq-100 ETF, with tight spreads and a reasonable 0.82% yearly fee. TQQQ has outperformed QQQ and peers over the past 15 years, driven by a secular tech bull market and recently AI. This made me rethink my approach to leveraged investing. For short-term AI rebound trades, I still favor SOXL over TQQQ; semiconductors capture the most upside if an AI hype cycle is to reignite. Long term, I am considering TQQQ.
Celestica Expands AI Infrastructure Portfolio: Will it Fuel Revenues? — Positive
CLS Zacks Investment Research — November 18, 2025CLS' new SD6300 storage system targets soaring AI data needs with an ultra-dense design aimed at boosting performance and cost efficiency.
Are You Looking for a Top Momentum Pick? Why TIM S.A. — Positive
TIMB Zacks Investment Research — November 18, 2025Does TIM S.A. Sponsored ADR (TIMB) have what it takes to be a top stock pick for momentum investors?
Oric Pharmaceuticals (ORIC) Upgraded to Buy: Here's What You Should Know — Positive
ORIC Zacks Investment Research — November 18, 2025Oric Pharmaceuticals (ORIC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TriMas (TRS) Upgraded to Strong Buy: What Does It Mean for the Stock? — Positive
TRS Zacks Investment Research — November 18, 2025TriMas (TRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
First Bank (FRBA) Upgraded to Strong Buy: Here's What You Should Know — Positive
FRBA Zacks Investment Research — November 18, 2025First Bank (FRBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know — Positive
ADCT Zacks Investment Research — November 18, 2025ADC Therapeutics (ADCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know — Positive
ANIP Zacks Investment Research — November 18, 2025ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Ares Commercial Real Estate (ACRE) Upgraded to Buy: What Does It Mean for the Stock? — Positive
ACRE Zacks Investment Research — November 18, 2025Ares Commercial Real Estate (ACRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock — Positive
JBIO Zacks Investment Research — November 18, 2025Jade Biosciences, Inc. (JBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Virgin Galactic (SPCE) Rating Upgrade to Buy — Positive
SPCE Zacks Investment Research — November 18, 2025Virgin Galactic (SPCE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).